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Mitochondrial fatty acid oxidation (FAO) plays an important role in
maintaining metabolic homeostasis, especially during catabolic stress. Genetic
mutation in gene that encodes for mitochondrial FAO enzymes could result in
metabolic stress especially during fasting or hypoglycemic condition. Mutation in
the active site residue (1528G>C) of long chain 3-hydroxy acyl CoA
dehydrogenase (LCHAD) results in the loss of LCHAD enzyme activity.
Children’s with LCHAD mutation were known to accumulate 3-hydroxy fatty acids
such as 3-hydroxy palmitic acid and 3-hydroxy myristic acids, long chain free
fatty acids, acyl carnitine and 3-hydroxy dicarboxylic acid due to their defective
enzyme activity. These accumulated 3-hydroxy fatty acids and long chain free
fatty acids are toxic compound to the cellular tissues and results in the
development of retinopathy. Here we hypothesize that increased levels of 3hydroxy fatty acid due to a mutation in LCHAD would induce retinal pigment
epithelial cell lipoapoptosis and palmitoleate (PO) protects against 3-hydroxy
fatty acid-induced retinal lipoapoptosis. Normal human immortalized retinal
pigment epithelial cells (ARPE-19) were treated with 3-hydroxy fatty acid (3-HFA)

for 24 hours and biochemical markers of lipoapoptosis such as characteristic
nuclear morphological changes of apoptosis and caspase 3/7 activity were
measured. Mitochondrial bioenergetics were assessed using Seahorse XF24
extracellular flux analyzer and lipid droplets were stained with oil red ‘O’ dye.
After 24-hours of 3-HFAs treatment to ARPE-19 cells, we observed a significant
increase in percent apoptotic nuclei and caspase 3/7 activity compared to the
vehicle treated cells suggesting retinal lipoapoptosis. Further, percent cell
survival and metabolic activity were decreased in cells treated with 3-HFA
compared to vehicle treatment. 3-HFA-induced retinal cell lipoapoptosis is cJun
N-terminal kinase- and caspase-dependent lipoapoptosis. Treatment of 3-HFAs
to retinal cells showed decreased mitochondrial bioenergetics as evidenced by a
decrease in basal respiration, ATP production, maximal respiration and
mitochondrial coupling efficiency compared to vehicle (p <.05). We also observed
that PO protects against 3-HFA-induced retinal lipoapoptosis. However further
investigations are required to understand the mechanism of palmitoleate
protection. In conclusion, 3-HFAs induce lipid droplet accumulation and
mitochondrial stress resulting in retinal pigment epithelial cell lipoapoptosis,
which was protected with PO supplementation.
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1. CHAPTER I: INTRODUCTION

1.1 Fatty Acid (FA) Metabolism
Metabolism is the set of chemical reactions that occur within living cells in
order to convert food into energy for the cellular processes (catabolism) and to
convert small nutrients into larger molecules (anabolism). In living organisms,
fatty acids (FAs) are essential components and building blocks for cellular
membranes and provide energy for the body. Fat lipolysis is the biochemical
process that takes place in the cytoplasm where the large fatty molecules such
as triglycerides can be broken down and hydrolyze into glycerol and three
molecules of fatty acids (FAs) in which enters mitochondria for its metabolism.
The FAs are metabolized by three types fatty acid oxidation pathways such as
mitochondrial-β oxidation, microsomal ω- oxidation and peroxisomal betaoxidation, these pathways are different from each other and these differences are
illustrated if Table 1. Mitochondrial β-oxidation is the most important pathway in
living organisms which oxidizes the released FAs into two carbon units of acetyl
CoA. Fatty acid oxidation (FAO) occurs with help of multiple enzymatic reactions.
Translocation of fatty acids across the mitochondrial outer and inner membrane
were carried out with the help of carnitine palmitoyl-transferase I and II (CPT
I&II). Long-chain fatty acyl-carnitine enters the mitochondrial outer membrane by
binding to carnitine via CPT-I and CPT-II translocase that transfer the fatty acylcarnitine into the mitochondrial matrix, where Beta-oxidation pathway takes
place. In this pathway, two carbons are cleaved from the long-chain acyl-CoA to
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form acetyl-CoA by breaking the bond between beta carbon and gamma carbon.
Thus, formed acetyl-CoA can enter tricarboxylic acid cycle in the mitochondrial
matrix.

Table 1 Comparison of Fatty Acids Oxidation Pathways

Location

Substrate

Benefits

Deficiencies

BetaOxidation
Mitochondrial
matrix for all
tissues except
erythrocyte and
adrenal medulla
Long, medium,
short chain fatty
acids
Major pathway to
maintain
mitochondrial
homeostasis and
production of
ATP

HADHA
deficiency
Systemic
carnitine
deficiency,
carnitine cycle
disorder

OmegaOxidation

PeroxisomeOxidation

Microsomes

Peroxisome

Long and very
long fatty
acids
Oxidation of
omega
carbon, when
beta-oxidation
defect, this
pathway
becomes
active

Bile acids
intermediates, very
long fatty acids

---------

Oxidation of the beta
carbon of the fatty
acyl CoA molecule

Zellweger syndrome
X-linked
adrenoleukodystrophy
(X-ALD), Acyl-CoA
oxidase deficiency
(ACOX1) deficiency,
diastolic blood
pressure (DBP)
deficiency
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1.1.1 Mitochondrial Fatty Acid Oxidation
Mitochondrial β-oxidation is the predominant FA oxidation pathway for
cellular energy needs, plays an important role in maintaining metabolism
homeostasis, especially during catabolic stress situations such as infection,
disease, exercise, and fasting conditions. A large number of fatty acid oxidation
disorders (FAODs) have been associated with a genetic defect in enzymes
involved in fatty acid oxidation pathways (Wilcken, 2010). Mitochondrial
trifunctional protein (MTP) is one of the complex enzymes that is required for the
mitochondrial fatty acid oxidation (FAO). MTP is a multi-enzyme complex located
in the mitochondrial inner membrane as a hetero-octamer and it contains four
subunits: alpha-subunits and four beta-subunits. Alpha subunit contains enoylCoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activity and beta subunit
has 3-ketoacyl CoA thiolase activity. The oxidation involves four main enzymes
and they are acyl-CoA dehydrogenase, enoyl-CoA hydratase and 3-hydroxyacylCoA dehydrogenase, and thiolase respectively. Any deficiency in one of these
enzymes results in blockage of FAO process leading to fatty acids oxidation
disorders. FAO is highly active in major metabolic organs like heart, liver and
muscle cells and therefore FAO disorders that are associated with beta-oxidation
are mostly expressed in the organs that relay on FAs metabolism predominantly
affects liver, heart, and muscles (Wajner & Umpierrez, 2016).
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1.1.2 Fatty Acid Oxidation Disorders (FAODs)
FAODs are inherited metabolic diseases that are classified as inborn
errors metabolism. FAODs are autosomal recessive genetic disorders which are
caused as result of defects in genes that encodes mitochondrial FAO enzymes.
The incidence of FAODs is about 1 in every 10,000 individuals (Merritt, Norris, &
Kanungo, 2018). There are more than fifteen different FAODs, the most
common disorders are short-chain acyl-CoA dehydrogenase (SCAD), mediumchain acyl-CoA dehydrogenase (MCAD), long-chain 3-hydroxy acyl-CoA
dehydrogenase (LCHAD), and very long-chain acyl-CoA dehydrogenase
(VLCAD) deficiency (Wajner & Umpierrez, 2016). The four most common
enzyme deficiencies are carnitine palmitoyl transferase 2 (CPT-II), very longchain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA
dehydrogenase (LCHAD), and mitochondrial trifunctional protein (MTP).
Individuals with FAOD accumulate toxic compounds in their circulations such as
fatty acids and fatty acyl-carnitine. These disorders can be diagnosed in early
stage of newborn life through laboratory analysis by measuring the levels of free
fatty acids, dicarboxylic acid, and acyl-carnitine metabolites in blood and urine
sample using Tandem Mass Spectrometry and Gas Chromatography (Enns et
al., 2000).
Newborns who are diagnosed with FAOD usually have a multi-organ
failure with a wide range of severity such as fatigue, hypoglycemia,
rhabdomyolysis, hepatopathy, cardiomyopathy, and skeletal myopathy. These
symptoms are mostly associated and worsened by fasting, infection, cold
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exposure, exercise, infections, and other catabolic situations that require a high
energy usage. Majority of the studies have indicated that the most associated
reason for pathophysiology in FAODs is energy deficiency. Further,
accumulating evidence that indicate the role of toxic fatty acids and fatty acyl
carnitine metabolites in disturbing mitochondrial homeostasis which results in the
development of most pathophysiology of FAODs (Wajner & Umpierrez, 2016).

1.1.3 Long Chain 3-Hydroxy Acyl-CoA Dehydrogenase Deficiency (LCHAD)
Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency (LCHAD) is a
disorder that is characterized by lack in LCHAD enzyme activity that is required
for fatty acid β-oxidation in the mitochondria. The incidence of LCHAD mutation
is 1:50,000 newborns (Hagenfeldt, Venizelos, & Von Dobeln, 1995). LCHAD is
inherited disorder that has homozygous mutation in HADHA gene c.1528G>C
affecting LCHAD enzyme activity (Padmini et al., 2015). As a result of this
disorder, the body can’t utilize long-chain fatty acids resulting in their
accumulation as acyl-carnitine and long chain fatty acids in the systemic
circulation.
Clinical presentations of LCHAD deficiency involves pathologies of the
organs that relay on the mitochondria for energy supply including heart, muscle,
liver, and eye. LCHAD deficient individuals usually present with common
features; hypoglycemia, metabolic acidosis, skeletal myopathy, hypotonia,
cardiomyopathy and hepatic steatosis, adipose tissue accumulation, retinopathy,
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exercise intolerance and neuropathy (Wilcken, 2010) (Waisbren, Landau, Wilson,
& Vockley, 2013).

1.2 Apoptosis
Apoptosis is a programmed cell death process that maintains cell
homeostasis during growth and development by eliminating severely damaged
cells. In early phase of apoptosis, mitochondria activate the release of caspases
by initiating caspase cascade resulting in pro-apoptotic signaling as a death
response (Solary, Bertrand, Kohn, & Pommier, 1993) (Gavrieli, Sherman, & BenSasson, 1992). Caspases are found as inactive proenzymes, during apoptosis,
the activation of the caspase is required to cleave many proteins out of the
mitochondrial membrane. After caspase activation, morphological changes occur
like cell shrinkage, nuclei condensation, and DNA fragmentation. Then, vital
caspase substrates in the cells is cleaved by the active caspase’s resulting in the
release of apoptotic bodies, which spread rapidly as a result of phagocytosis of
neighboring cells. Apoptosis occurs primarily via two main pathways namely
extrinsic and intrinsic pathway of apoptosis as illustrated in Figure 1. Both
pathways are initiated by different mechanisms and signals which activate the
caspases 3 and 7 that cleave more than 1000 proteins leading to changes in cell
morphology indicating apoptosis (Kalkavan & Douglas, 2017).
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Active caspase 9

Pro-caspase 9

Figure 1 The extrinsic and intrinsic apoptotic pathways. At the plasma
membrane, extrinsic pathway is activated when death receptors ligands bind to a
subset of tumor necrosis factor receptor (TNF) receptors including TNFR1, Fas
receptor, and death receptors. These receptors activate the procaspases 8 and
10 which leads to the activation of caspase 3 and 7 resulting in apoptosis.
Intrinsic pathway is modulated by cell stressors such as Endoplasmic reticulum
stress, DNA damage, nutritional stress and hypoxia. Mitochondrial outer
membrane permeabilization (MOMP) occurs via the interaction of pro-apoptotic
BH3 containing proteins such as BAX and BAK and BAX/BAK oligomerization.
Pro-apoptotic intermembrane space (IMS) releases Cytochrome c (Cyt c) and
second mitochondria-derived activator of caspase (SMAC) resulting in activating
procaspase 9. Active caspase 9 cleaves pro-caspase 3 and 7 resulting in their
activation for caspase-dependent apoptosis. This figure is adopted and modified
from (Kalkavan & Douglas, 2017).
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1.2.1 Extrinsic and Intrinsic Pathway of Apoptosis
The extrinsic pathway or death receptors pathway of apoptosis is initiated
by the activation of death receptors (DRs) at cell membrane including tumornecrosis factors (TNF), TNFR1, Fas receptor, CD95, and TRAIL receptors,
respectively. These receptors play a critical role in communicating death signals
from cell surface into mitochondria (Saraste, 1999). Once the subset of these
receptors is activated by ligand binding in the plasma membrane, the activation
of procaspase-8 or 10 takes place leading to their substrate caspase 3 and 7
cleavage and activation for the induction of apoptosis.
The intrinsic pathway of apoptosis is a response to internal damage and
stressors such as damaged DNA, damaged chromosome, and ER- stress. As a
result of the cell sensation to the internal stressors, the interaction of BCL-2
family members such as the activation of BH3 domain containing pro-apoptotic
proteins; BAX and BAK, and results in the formation of mitochondrial outer
membrane permeabilization pore (MOMP). Consequently, the releases of
apoptogenic factors such as cytochrome c, second mitochondria-derived
activator of caspases (SMAC) (Kroemer et al., 2009) and apoptosis-inducing
factor (AIF) from the mitochondria are induced (Kalkavan & Douglas, 2017;
Saraste, 1999) . These proteins induce caspase dependent and independent cell
death by generating reactive oxygen species (ROS) and cytochrome which
eventually trigger caspase 3 activation. The activated caspases cleave proteins
that stimuli apoptosis and result in abnormalities in genome DNA. However, both
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intrinsic and extrinsic pathways activate caspase cascade leading to programed
cell death.

1.3 Mitochondria
Mitochondria is an important organelle to maintain cellular homeostasis, to
produce adenosine triphosphate (ATP), to regulate redox and calcium
homeostasis, cellular metabolism, and apoptosis. Mitochondria has unique
function for lipid metabolism where fatty acids oxidation takes place. The integrity
and the quality of mitochondria are controlled through many cellular and
molecular pathways (Radek et al., 2014).Mitochondria is considered as a clock
that affect the lifespan of cellular processes, any disturbance in the mitochondrial
function can result in the development of metabolic disorders (Blagosklonny,
2008). Defect in mitochondrial performance results in altered redox hemostasis
leading to the generation of reactive oxygen species (ROS) (Radek, Marco, &
Heinz, 2014). Further, mitochondria have also been demonstrated to regulate
intracellular signaling via Ca2+ and ROS (Tait & Green, 2012). Abnormal levels
of ROS generation can impact the mitochondrial processes causing a disruption
in respiratory chain, and activate apoptotic process (Friedman & Jodi, 2014). It is
important to control mitochondrial integrity to maintain cellular homeostasis. The
manifestation of a variety of human diseases can impair the quality control
system of the mitochondria.

10
1.3.1 Mechanisms of Mitochondria in Inducing Pathophysiology
In LCHAD disorder, the mitochondria are involved in mechanisms of
inducing apoptosis and lipotoxicity. Although energy deficiency seems to play a
major role in development of pathophysiology especially in hepatopathy
cardiomyopathy of the affected patients (Wilcken et al., 2007)and skeletal
myopathy (Spiekerkoetter et al., 2010), central and peripheral neuropathy are not
associated with caloric intake and hypoglycemia (Wajner & Umpierrez, 2016).
Therefore, it is possible that there are mechanisms other than energy deficiency
could contribute to the pathogenesis of LCHAD deficiency. It has been suggested
that mitochondrial stress and accumulation of metabolites compounds such as
fatty acids and carnitine might be the mechanisms that induce pathogenesis in
LCHAD deficient individuals (Spiekerkoetter & Wood, 2010); (Olpin, 2013).
Wajner et al., summarized the recent evidences of the mechanisms that
affect energy homeostasis and lead to pathophysiology. The gathered data was
based on patients and animal models with mitochondrial disorders suggesting
that the mechanisms to disorders might be redox reactions, fatty acid
accumulation, calcium homeostasis, and energy deficiency. Figure 2 illustrates
the major roles of accumulated fatty acids metabolites inducing lipotoxicity
resulting in energy and mitochondrial damage (Wajner & Umpierrez, 2016).
LCHAD deficient individuals develop mitochondrial dysfunction and energy
deficiency. Further, biochemical and mitochondrial morphological alterations
were also observed in LCHAD deficient patients’ heart, skin fibroblasts, and
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muscle tissues (Derks et al., 2014);( Najdekr et al., 2015);( Feillet et al.,
2003);(Wakabayashi et al., 2012); (Ruitenbeek et al., 1995).

Figure 2 Mitochondrial dysfunction provoked by fatty acids and acyl
carnitines accumulating in FAOD. In defective fatty acid oxidation (FAO)
pathway, the acyl-CoA can’t be converted into Acetyl-CoA resulting in higher
accumulation of the substrates such as acyl carnitines and fatty acids. The
accumulation of these compounds is toxic to the heart, liver, muscle, and brain
tissue’s that relay on fatty acids for energy. This lipotoxicity alters the
mitochondrial bioenergetic functions and increases oxidative stress. This figure is
adopted from (Wajner & Umpierrez, 2016).

Further, oxidative phosphorylation (OXPHOS) takes a place in the
mitochondria to produce ATP and reactive oxygen species (ROS) through
respiration chain. The ROS plays an important role in regulating gene and
enzyme activity, increased free radical production and decreased ATPproduction would lead the cells to a cascade of apoptosis or necrosis (Natarajan,
Eapen, Pullimood, & Balasubramanian, 2006). Collectively, these published
evidences ensure how mitochondria and energy disturbance are associated with
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pathophysiology in the tissues that primarily relay on the mitochondrial fatty acid
β-oxidation like LCHAD deficient patients.

1.3.2 Role of Mitochondria in Fatty Acid Oxidation Disorder
Individuals with LCHAD deficiency accumulate lipotoxic compounds such
as fatty acids and acyl carnitines in the systemic circulation and tissues which
might induce cellular lipotoxicity (Lipoapoptosis). There are many evidences
supporting the role of accumulated fatty acids and acyl carnitines compounds in
distressing mitochondrial homeostasis mainly on the brain, liver, and skeletal
muscle. Meyer et al., isolated retinal cells from early forebrain populations and
they used hiPSC cultures showing that excessive lipid load in non-adipose cells
such as retinal pigmented epithelial (ARPE) cells can impair normal cell signaling
leading to peroxidation, cellular dysfunction, and apoptotic cell death (Meyer et
al., 2011). Although non-adipose cells such as ARPE cells have limited capacity
for lipid storage, LCHAD deficient retinal cells have shown lipid accumulation
resulting in retinal atrophy (Meyer et al., 2011). Further, medium-chain acyl-CoA
deficiency (MCAD) results in the accumulation of medium fatty acids like octanoic
acid, decanoic acid, and cic-4-decanoic acid. These accumulated medium chain
fatty acids results in mitochondrial damage and induces BAX-BAK
oligomerization resulting in pore formation in the mitochondrial outer membrane
and alters the mitochondrial permeability transition (mPT) (Parker, W., Haas,
Stumpf, & Eguren, 1983); (Schuck, Ferreira Gda et al., 2009); (Schuck et al.,
2010); (Schuck, Ferreira et al., 2009). Wajner et al, postulated that LCHAD
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deficient accumulate 3-hydroxy fatty acids like 3-hydroxydodecanoic acid, 3hydroxy myristic acid, and 3-hydroxy palmitic acid. Further, in LCHAD deficient
animals, it was shown that hydroxy fatty acids can disturb energy and redox
homeostasis (Wajner & Umpierrez, 2016). These hydroxy fatty acids were shown
to uncouple mitochondrial oxidative phosphorylation (OXPHOS), induces mPT
and oxidative stress leading to the pathophysiology of cardiac, hepatic, and
myopathic in LCHAD deficient individuals. In addition to hydroxy fatty acids,
carnitine derivatives also accumulate in tissue causing disturbance to the
mitochondria and Ca+2 homeostasis (Wajner & Umpierrez, 2016). Further,
lipotoxic lipid metabolites induces mitochondrial abnormalities leading to many
events including uncoupling of OXPHOS, decreases respiratory chain activity,
and nicotinamide adenine dinucleotide (NAD+) levels (Touma & Charpentier,
1992); (Trauner, Nyhan, & Sweetman, 1975).
Our lab has previously published that long-chain fatty acids e.g., palmitic
acid and arachidonic acid were elevated during acute fatty liver of pregnancy
(AFLP) or LCHAD deficiency. We also have unpublished data on the mechanism
of 3-hydroxy fatty acid-induced hepatocyte lipoapoptosis (Natarajan & Ibdah,
2018). Further, our lab has also established the lipotoxic role of palmitic acid in
causing hepatocyte and cholangiocyte lipoapoptosis by the activation of mitogenactivated protein kinase (MAPK), and forkhead family of transcription factor class
O3 (FoxO3) dependent pro-apoptotic signaling pathway (Natarajan et al., 2014);
(Natarajan et al., 2017). Another study demonstrated that the major accumulating
lipotoxic metabolites during LCHAD deficiency is 3-hydroxymyristic acid (3-HMA)
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and 3-hydroxypalmatic acid (3HPA) in the circulation and these 3-hdyroxy fatty
acids were also found to accumulated in different tissues, and significantly affects
mitochondrial homeostasis (Hickmann et al., 2015). Collectively, it has been
demonstrated that the lipotoxicity of 3-hydroxy fatty acids and acyl carnitine
metabolites were more likely to be involved in the pathogenesis of LCHAD
deficient individuals.

1.4 Retinal Pigmented Epithelial Cells in LCHAD Deficiency
Retinal pigmented epithelium (ARPE) is a monolayer of cells that are the
main nutrient provider for the retina in eye. Melanin display potential antioxidant
roles including inhibition of oxidation, remove redox-active metal ions, and
protect against free radicals in retinal pigment epithelium (RPE). Development of
retinopathy is highly associated with LCHAD deficiency but not with other fatty
acid oxidation disorders (FAODs) (Padmini et al., 2015). The LACHD inherited
deficiency has been reported to develop pigmentary retinopathy leading to vision
loss without early intervention, high myopia, poor vision, and chorioretinal
atrophy (Tyni et al., 1998). Tyni et al., have also demonstrated the fatty acid
oxidation enzymes in retinal pigment epithelial cells including carnitine palmitoyl
transferase (CPT-I and CPT-II) and all mitochondrial beta-oxidation enzymes
(Tyni, Paetau, Strauss, Middleton, & Kivela, 2004).
The pigmentation in RPE tends to decrease with aging leading to vision
degradation (Padmini et al., 2015) and patients with LCHAD deficiency develop
different stages of pigment retinopathy (Tyni, Immonen, Lindahl, Majander, &
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Kivela, 2012). Further, severity of retinopathy and staging for chorioretinopathy
were documented in LCHAD deficient individuals. The RPE of patient with
LCHAD deficiency at early stage showed retinopathy with less pigmentation and
less atrophy. The RPE of patient with LCHAD in advance stage displayed severe
retinopathy, dramatic pigmentation and damage in the retinal cells. However, the
mechanism behind the retinopathy in LCHAD deficiency is still unclear. Also, it
has been suggested that the accumulation of toxic long chain fatty acids (LCFA)
and 3-hydroxy fatty acids (3-HFA) might be a possible mechanism behind
retinopathy (Den et al., 2002);(Schrijver-Wieling et al., 1997). Based on this
literature we hypothesized that defective mitochondrial fatty acid β-oxidation and
the accumulation of 3-hydroxy fatty acid in the retinal epithelium can induce the
development retinopathy in LCHAD deficient individuals.

1.4.1 Apoptosis of Retinal Cells in LCHAD Deficiency
Padmini et al., has isolated human induced pluripotent stem cell (hiPSC)
from LCHAD deficient individuals and differentiated hiPSC into RPE cells to
create LCHAD deficient in vitro culture model (Padmini et al., 2015). These cells
were derived from patients with homozygotes mutation in HADHA gene. The
study compared control RPE cells to the cells derived from LCHAD deficient
individuals and characterized the RPF cell structure and functional alterations.
The differentiated RPE from LCHAD deficient individuals displayed increased
lipid accumulation, less pigmentation, few melanosomes, retinal atrophy and
increased RPE apoptosis. They also observed mitochondrial damage and
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decreased mitochondrial oxidant scavenging are potential as a mechanism of
retinopathy. In summary, PRE cells from patients with LCHAD deficiency showed
mitochondrial damage increased lipid accumulation, decreased melanosome,
and apoptosis.

1.5 Dietary Supplementation as a Protective Strategy Against LCHAD
Deficiency
The main strategy for patients with LCHAD deficiency is to avoid energy
complications. Dietary management of LCHAD involves long chain fatty acids
(LCFA) restrictions and avoids catabolic crises such as fasting by giving
adequate supply of calories from carbohydrate and medium chain fatty acids
(MCFA) (Wajner & Umpierrez, 2016). However, giving glucose polymers is not
recommended to be supplemented habitually, instead, oral prophylactic is
suggested for emergency treatment (Spiekerkoetter et al., 2009). To prevent or
slow the progression of chorioretinopathy and other pathologies that are
associated with LCHAD deficiency, patients are recommended to follow a very
low-fat diet (10% of total energy) supplemented with medium chain fatty acids
(MCFA) (10% of energy) (Wajner & Umpierrez, 2016).

1.5.1 Medium Chain Fatty Acid (MCFA) Supplementation
Exercise requires higher energy supply, it has been reported that MCFA
supplementation is enough to provide sufficient energy for prolonged period of
exercise in patients with very long-chain acyl-CoA deficiency (VLCAD)
(Spiekerkoetter, 2007). Therefore, supplementing with MCFA is important for
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optimal health needs for VLCAD deficient individuals (Lindner et al., 2009).
Further, the destruction of muscle cells that are resulted from exercise can be
inhibited by taking adequate amount of MCFA before the exercise in LCHAD
deficient individuals (Gillingham, Scott, Elliott, & Harding, 2006). Since the fat
intake is restricted, patients with LCHAD need to be supplemented with fatsoluble vitamins. In addition, Triheptanoin (UX007) is a drug composed of
medium chain triglyceride that possesses the gluconeogenic and ketogenic role
because it provides alternative substrates during increased energy needs and
during fasting. It has been shown that UX007 can reduce hypoglycemia,
rhabdomyolysis, and cardiac functions and improves endurance exercise and
tolerance in patients with severe LCHAD deficiency (Vockley et al., 2017).

1.5.2 Carnitine Supplementation
Carnitine supplementation might be beneficial for detoxification of the toxic
3-hydroxy fatty acids and long chain fatty acids compounds from the circulation
(Spiekerkoetter & Wood, 2010). On other hand, L-carnitine was found to worsen
the health by accumulating toxic long-chain carnitine substrates (Treem et al.,
1996); (Rocchiccioli et al., 1990). However, further study needs to be explored to
understand the protective role of carnitine against lipotoxic 3-hydroxy fatty acids
metabolites in retinal pigment epithelial cells.
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1.5.3 Docosahexaenoic Acid Supplementation
The beneficial role of docosahexaenoic acid (DHA) has been explored in a
prospective cohort study for the retinal function in children’s with LCHAD
deficiency. The authors demonstrated that DHA-supplemented patients with
LCHAD deficiency showed reduced the retinal complications (Gillingham,
Weleber, & Neuringer, 2005).It was also demonstrated that the severe
progression of chorioretinopathy was associated in patients with elevated 3hydroxy-acylcarnitines. Further, levels of 3-hydroxyacylcarnitines and 3-hydroxy
fatty acids were directly proportional with severity of retinal atrophy (Gillingham et
al., 2005); (Jones et al., 2000); (Jones et al., 2001). These data suggest the
3-hydroxy fatty acids is toxic to the retina and RPE cells and supports our
hypothesis of the present study.
The dietary recommendations for LCHAD deficient patients highlighted in
the previous sections are still not a mechanism based. Additionally, many
patients still experiencing hospitalization due to shortage in energy supply and
accumulation of toxic 3-hydroxy fatty acids compounds (Kinman et al., 2006; Roe
& Brunengraber, 2015). Our long-term goal is to develop a nutraceutical
approach to prevent 3-hydroxy fatty acid-induced retinal pigment epithelium
damage.

1.5.4 Protective Role of Palmitoleate Supplementation
Palmitoleic acid (PO) is a monounsaturated omega-7 fatty acid that
present in animal fat, plant oil, and macadamia nuts. It can be synthesized from
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palmitate C16 (saturated fatty acid) by the enzyme stearoyl CoA-desaturase
(SCD1). PO is involved in many processes associated with cell function such as
growth, signaling, storage, and cell differentiation. It has been demonstrated that
PO acts as anti-apoptotic fatty acid that improves lipid profile in metabolic
disease animal models (Morgan, Dhayal, Diakogiannaki, & Welters, 2008);
(Morgan & Dhayal, 2010). Zhi-Hong Yang et al. showed antidiabetic effect of PO
in KK-Ay mice that developed diabetes and hyperglycemia. Further, PO enriched
diet has been demonstrated to protect pancreatic beta cells from apoptosis,
improved hypertriglyceridemia, glycemic control, glucose uptake, and prevented
lipid accumulation in the liver in KK-Ay mice (Yang, Z. H., Miyahara, & Hatanaka,
2011). In comparison to palmitic acid (PA) a saturated fatty acids, PO has more
protective role against hepatic lipotoxicity and placental lipotoxicity (Yang, H.,
Miyahara, & Hatanaka, 2011); (Yang, Z. H. et al., 2011). Additionally, Yang et al.,
investigated in animals by orally administered vehicle (control), 300 mg/kg per
day of PA, or 300 mg/kg per day PO for 4 weeks to show the effect of palmitoleic,
acid on hepatic steatosis in KKAy mice. PO dramatically reduced lipid
accumulation in the liver of diabetic mice compared to control and PA
supplementation. In addition, PO supplementation also controlled lipogenesis
and prevented lipid accumulation in adipose tissue
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1.6 Central Hypothesis, Purpose, and Specific Aims
1.6.1 Central Hypothesis and Purpose
Retinopathy is very common characteristic in patients with LCHAD
deficiency that is not observed in other fatty acid oxidation defects. The retinal
damage in LCHAD deficient patients is associated with retinal pigmentation,
peripheral neuropathy, and cognitive deficiency (Tyni, Paetau, Strauss,
Middleton, & Kivela, 2004) (Natarajan & Ibdah, 2018). However, the molecular
mechanism behind the retinopathy in LCHAD deficiency still unclear.
Identification of the lipotoxic role of 3-hydroxy fatty acids (3-HFAs) may
offer new perspectives for potential mechanism and to develop new therapeutic
dietary strategies to LCHAD deficient patients. Hence, we hypothesize that the
increased levels of toxic 3-hydroxy fatty acid metabolites in LCHAD deficiency
can induce lipoapoptosis in retinal pigment epithelial cells. Despite the dietary
recommendations for patients with LCHAD with medium chain fatty acids
(MCFAs) supplementation, patients still experiencing hospitalization due to
shortage in energy supply and accumulation of toxic 3-HFAs metabolites.
Because MCFAs can be elongated to form long chain fatty acids (LCFAs).
Therefore, future prospective studies and development of approved treatment
strategies are needed. In terms of nutritional or dietary therapy, it has been
shown that palmitoleic acid (PO) has a beneficial role against lipid accumulation
in liver of diabetic mice and it also plays a protective role against hepatic lipid
droplets accumulations. We further hypothesized that PO protects against
3-HFAs induced retinal pigmented epithelial (RPE) cells lipoapoptosis.
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This master thesis underlines how the accumulated 3-hydroxy fatty acids
(3-HFAs) contribute to retinal pigment epithelial cell damage. To further
understand the mechanism of the damage, this study aimed to identify the
molecular mechanism of the 3-HFA-induced retinal pigment epithelial cell
lipotoxicity using human immortalized adults retinal pigmented epithelial cells
(ARPE-19). Further, the protective role of palmitoleic acid (PO) in reducing lipid
accumulation in retinal cells is also investigated. Further the role of p53
upregulated modulator of cJun N-terminal kinase (JNK) in 3-HFAs-induced RPE
lipoapoptosis is also investigated.

1.6.2 Specific Aims
The specific research objectives of this thesis are as follows:
•

Specific Aim 1: We will determine the mitochondrial bioenergetics of

retinal pigmented epithelial cells (ARPE-19) cells with 3-HFAs exposure.
•

Specific Aim 2: We will detect the role of 3-HFAs in inducing cell

apoptosis in ARPE-19.
•

Specific Aim 3: We will detect the lipid droplet accumulation in ARPE-19

cells with 3-HFAs treatment.
•

Specific Aim 4: We will elucidate the mechanism of 3-HFA-induced

ARPE cell lipoapoptosis is via caspase and JNK activation.
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2. CHAPTER II: MATERIALS AND METHODS

2.1 Cell Culture
2.1.1 Sub-Culturing Cells
Cell cultures were performed using normal human retinal pigmented
epithelial cells (ARPE-19) that were purchased from ATCC. The ARPE-19 were
grown as monolayer in medium Dulbecco's Modified Eagle's Medium (DMEM)
containing serum-supplement with 10% of FBS (fetal bovine serum), HEPES (4(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (15 mM) , sodium pyruvate
(0.5 mM) , and sodium bicarbonate (1200 mg/L). The cells were seeded in flask
with growth media and cultured in an environment with 5% CO2 at 37 °C. For
sub-culturing the cells; media was discarded using aspirator, the cells were
rinsed with PBS and incubated 1 mL of Trypsin for 1-2 minutes to allow the cells
to detach from the flask. After that, 5 mL of growth media was added, and cells
were re-suspended and cell suspension were centrifuged 500 x g for 5 minutes
to remove the supernatant and the cell pellets were resuspended with fresh
media and platted in new culture flask.

2.1.2 Counting Cells
The cells were counted using hemocytometer was placed under the
microscope with 10X objective to visualize the cells located in the chambers
indicated by gridlines square. Figure 3 (A) shows a schematic of the location of
the counted cells inside the chamber. After counting the cells in both chambers,
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the cells were averaged then multiplied by the following factors: dilution factor
(10X), mL-conversion factor (1000), and number of squares that contained
counted cells as shown in Figure 3 (B).

Cover glass

Chamber 1

1

2

3
4

5
(B)

Chamber 2

Induction port

(A)
Figure 3 Schematic of (A) Hematocytometer and (B) counting chamber.

2.1.3 Cell Seeding
ARPE-19 cells were seeded at density of 60,000 cells/well in 24-well plate
and 10,000 cells/well in 96-well plate containing DMEM media with volume of
500 µL/well in 24-well plate and 100 µL/well in 96-well plate, respectively.
Treatment of different 3-hydroxy fatty acids or fatty acids were performed after
the cells were attached to the plate.

2.2 Fatty Acids Preparations
Different types of fatty acids were used in the present study: 3-hydroxy
fatty acids (3-hydroxy palmitic acid and 3-hydroxy myristic acid), saturated fatty
acids (palmitic acid and myristic acid), and palmitoleic acid were treated as
described below.
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2.2.1 Treatment of 3-Hydroxy Fatty Acids (3-HFA)
The experiment was designed with two different conditions including a
vehicle control and 3-HFAs treatment. The vehicle cells were treated with only
isopropanol and 1% of bovine serum albumin (BSA) obtained from Millipore
Sigma. The ARPE-19 cells were treated with two different types of 3-HFA:
3-hydroxy palmitic acid (3-HPA) and 3-hydroxy myristic acid (3-HMA), both were
purchased from Cayman Chemical Company. These 3-hydroxy fatty acids were
dissolved in isopropanol with a stock solution of 80 µM. To treat the cells with 3HFA, 1% BSA containing growth media were preincubated at 37°C for 30
minutes and filter sterilized. BSA-containing media was is mixed with 3-HFA and
incubated at 37°C for another 20 minutes prior to the treatment.
The experiment was designed to treat ARPE-19 cells with different
concentrations of 3-HFA (150, 200, and 250 µM) for 24 hours as shown in Figure
4. After seeding the cells, the growth media was removed using aspirator then
3-HFA containing media were added to the wells.

Control
Control
150 µM
3-HPA

200 µM
3-HMA
250 µM

Figure 4 24-well format of a control and 3-HFA treatment in ARPE-19 cells.
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2.3 Apoptotic Nuclear Morphological Changes

Biochemical apoptotic nuclear morphological changes were detected after
24 hours of 3-HFAs treatment. Apoptotic morphology changes can be visualized
under microscope and that duration of time is varying based on cell type
(Saraste, 1999). Control and treated cells were stained with 5 μg /ml DNAbinding dye, DAPI (4′,6-diamidino-2 phenylindole) for 20-30 minutes at 37 ºC.
Nuclear images were obtained using epifluorescence microscopy using an EVOS
FL inverted microscope. Apoptotic nuclei were counted and presented as a
percent of total nuclei. At least 100 cells were counted per well and experiments
were performed in triplicate.

2.4 Measurement of Caspase 3/7 activity
Caspase 3/7 activity was measured by enzymatic fluorophore release
(Apo one, Promega, TB323) according to the manufacturer’s instruction
(Promega) and represented as fold change compared to vehicle treatment, with
experiments performed in quadruplicate as described (Promega, TB323). Briefly
caspase substrate and buffer were mixed with 1:100. After 24 hours of 3-HFA
treatment in ARPE-19 cells, mixed reagents (caspase substrate and buffer) were
added. To detect the enzymatic fluorophore release using Synergy-H1 Hybrid
Reader (BioTek)
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2.5 Mitochondrial Stress
All materials used in this experiment were provided from Agilent Seahorse
using XF Cell Mito Stress test kit. This experiment was carried out at Biomedical
and Obesity Research Core (BORC) facility at University of Nebraska-Lincoln.
Mitochondrial stress experiment was conducted according to Seahorse protocol
(Meerloo, Kaspers, & Cloos, 2011). The procedure includes cells platting, media
preparation, stock solutions preparation, and oxygen consumption rate
measurement.

2.5.1 Platting Cultures and Hydrating Sensor Cartridge
ARPE-19 cells were plated in Seahorse XF24 cell culture microplate with
100 µl/well density mixed with 150 µl/well of DMEM growth media, then cells
were incubated in 5% CO2 incubator for 8 hours for adherence. The sensor
cartridge of XF calibration plate was hydrated in 1ml/well of XF calibrant buffer,
that was premixed and provided from Agilent Seahorse, then the plate was
stored in non-CO2 incubator overnight for sensor calibration.

2.5.2 Preparing Assay Medium
XF base medium was supplemented with the following nutrients (Sigma);
Pyruvate (1 mM), Glutamine (2 mM) and Glucose (10 mM). The base medium
was warmed in water bath at 37°C for 5 minutes and the pH was adjusted to 7.4
and followed by filter sterilization. Cells were rinsed twice with the supplemented
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base media and stored in non-CO2 incubator for 1 hour prior to the mitochondrial
stress test.

2.5.3 Preparing Stock Compounds
The Seahorse XF Cell Mito Stress Test Kit includes pouches with three
tubes of Oligomycin (1 μM), Rotenone (0.5 μM), Antimycin (0.5 μM), and FCCP
(0.5 μM). Each compound was pipetted into 15 mL experiment tube with 3 mL of
XF base media with the following amounts; Oligomycin (1.24 µL), FCCP (0.67
µL), and Rotenone/Antimycin (1.5 µL). The previous volumes were calculated
according to table 5 in Seahorse protocol (Agilent Technologies, 2017). The
sensor cartridges were loaded with the prepared compounds into the appropriate
ports as described in the manufacture protocol (Agilent Technologies, 2017;

Agilent Technologies, 2018).

2.5.4 Running XF Assay and Measurement of Oxygen Consumption Rate
(OCR)
The XF calibration plate was removed from the non-CO2 incubator and
placed in Agilent Seahorse analyzer instrument tray for calibration for 10
minutes. After that, calibration plate was replaced by XF cell culture plate to
obtain oxygen consumption rate (OCR) measurement. The data of OCR for the
control and treated cells were obtained from Seahorse XF report generator. The
obtained data were analyzed following Seahorse protocol user guide (Agilent
Technologies, 2017).
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2.6 Western Blotting
2.6.1 Protein Isolation
Control and 3-hydroxy fatty acid-treated cells were washed with 3-5 mL of
cold phosphate buffered saline (PBS). Then, 1 mL of lysis buffer containing
HEPES, NaCl, tris—HCl and protease inhibitor mixture was added to the washed
cells. The cells were scraped with cell scrapper, transferred into microcentrifuge
tubes and incubated for 40 minutes to complete cell lysis. Cell lysates were
centrifuged at 12,000 X at 4°C for 20 minutes. After centrifugation, tubes were
placed on ice and the supernatant was transferred into a new microcentrifuge
tubes in ice for protein estimation and western blot analysis.

2.6.2 Protein Estimation
Total proteins in cell lysates were quantified using bovine serum albumin
(BSA) as standard using pierce 660nm (ThermoFisher) as described in BIO
protocol (He, 2011). Briefly, to a 200 µL of Pierce protein assay reagent, 2 μl of
cell lysate and incubated for 5 minutes, then absorbance was measured at OD
595 nm using Synergy-H1 Hybrid Reader.

2.6.3 Sodium Dodecyl Sulfate-Polyacrylamide gel electrophoresis (SDSPAGE) Gel and Immunoblot analysis:
Protein gel electrophoresis is a technique used to separate the proteins
based on their molecular weights through the electrical field to detect the protein
of interest. Prior to gel electrophoresis, a 25 μL of molecular weight marker and
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protein samples were loaded into wells of SDS-PAGE gel (Invitrogen), then
placed into electrophoresis apparatus to be electrophoresed for 2 hours at 100 V.
Upon applying the electrical voltage, proteins in the wells migrates down through
the gel as shown in Figure 5.
Next, the gels were transferred to the nitrocellulose membrane (BioRad).
The proteins were transferred from the gel to a membrane by making transfer
sandwich stack. The sandwich was placed into a transfer tank that filled with
transfer buffer (wet method), with 100 V for 1 hour at 4°C. Transferred membrane
were blocked with 5% milk powder dissolved in TBST for 1 hour at room
temperature prior to immunoblotting detection.

⁻

⁺

Loaded samples

Running
buffer
Electrophoresis tank

Figurer 5 Schematic representation of SDS-PAGE gel and loading wells.

2.6.4 Immunoblot Detection
Transferred membranes were incubated at 4°C overnight with primary
antibodies against cleaved PARP, Cleaved Caspase 3, and PUMA (1:1000
dilution in5% milk solution). After that, membrane was washed with TBST three

30
times with 10 minutes interval. After washing respective secondary antibody
conjugated with horse radish peroxidase was added and incubated for 2 hours at
room temperature. After washing the membrane with TBST three times for 10
minutes. Detecting membrane bands was accomplished by adding 1 mL of
Clarity Western ECL Substrate. Membrane were incubated with 1 ml of solution
A & B in Clarity Western ECL Substrate kit containing hydrogen peroxide and
luminol were exposed to autoradiography and chemiluminescent images were
captured with using ChemiDocTMTouch Imaging System (BIO-RAD).

2.7 Oil Red O Staining
A stock solution of oil red O was prepared by dissolving 0.5 g of oil red O
in 100 mL of isopropanol, then the mixture was filtered through whatman filter
paper. From the stock solution, 6 mL of oil red O was mixed with 4mL of water.
After 24 hours of 3-hydroxy fatty acids treatment, cells were fixed with 2mL/wall
of 10% buffered neutral formalin for 30 minutes, then washed with PBS twice.
Intracellular lipid droplets in retinal cells were stained with 2mL/ Oil Red O
solution at room temperature for 20 minutes, then washed four times with distilled
water. Cells were mounted using Fluoromount-G and coverslips and the images
were captured using EVOS XL microscope with 40X objective in Dr. Chung’ lab
in the Department of Nutrition & Health Sciences at the University of NebraskaLincoln facility.
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2.8 Measuring Cell Survival Using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) Assay
To prepare 12 mM stock solution of MTT assay, 1 mL of PBS was added
to 5 mg of MTT, then it was vortexed. After ARPE-19 cells were treated with 3HPA and 3-HMA for 24 hours, the media was removed and 100 μL of MTT
reagent was added to each well, then incubated for 4 hours. The Formazan
formed were with 100 μL of isopropanol then stored at room temperature at dark
place for 2 hours. The absorbance was measured at OD 570 nm using SynergyH1 Hybrid Reader (BioTek).

2.9 Z-VAD and JNK Inhibitors
ARPE-19 cells were treated with 3-HPA or 3-HMA or vehicle (Veh) with or
without 50 µM of pan-caspase inhibitor Z-VAD-fmk (Z-VAD) or JNK inhibitor
(SP600125) for 24 hours. Caspase 3/7 activity and cell survival were measured
as described above in (E and I).

2.10 Statistical Analysis
Data were presented as mean ± standard error of mean (SEM). The
statistical analysis was performed using one-way analysis of variance (ANOVA)
with p-value was tested at level 5% * P < 0.05. Tukey post hoc correction were
carried out to test the statistical significance and to avoid false positives.
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3. CHAPTER III: RESULTS

3.1 Results
3.1.1 Treatment of 3-Hydroxy Palmitic Acids (3-HPA) Decreased
Mitochondrial Bioenergetics in Retinal Pigmented Epithelial Cells (ARPE19)
To investigate the effect of 3-hydroxy palmitic acids (3-HPA) on
mitochondrial function in retinal pigmented epithelial cells (ARPE-19), in vitro
mitochondrial stress test was performed to measure oxygen consumption rate
(OCR) using Seahorse XF24 Extracellular Flux Analyzer to quantify OCR under
basal conditions. Treatment of 3-HPA to ARPE-19 cells resulted in a significant
decrease in mitochondrial OCR detected over 100 minutes Figure 6 (A). Further,
treatment of 3-HPA to APRE-19 cells showed a significant decrease in basal
respiration, maximal respiration, adenosine-triphosphate (ATP) production, and
coupling efficiency compared to vehicle (veh) Figure 6 (B, C, D, and E). Vehicle
treatment contains equal amounts of isopropanol used to dissolve 3-hydroxy fatty
acids in 1% BSA containing media for 24 hours. On the other hand, there was a
non-significant decrease in spare respiratory capacity and proton leak in ARPE19 cells treated with 3-HPA compared to vehicle treatment Figure 6 (F and G).
These data suggest that 3-HPA induces mitochondrial damage and results in
altered mitochondrial bioenergetics.
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Figure 6 Mitochondrial bioenergetics functions in ARPE-19 cells treated
with 3-HPA. A) Oxygen consumption rate (OCR) for 100 minutes in vehicle and
3-HPA treated ARPE-19 cells. B) Basal respiration (B), Maximal respiration (C),
ATP production (D), Coupling efficiency (E), Spare respiratory capacity (F) , and
Proton Leak of ARPE-19 cells treated with 3-HPA and compared with vehicle
ARPE-19 cells, respectively* indicates P-value with different level of significance
compared to vehicle treatment, *(<0.05). ** (<0.01), and ***(<0.001). The data is
represented mean ± SEM from five independent experiments, n=5.The statistical
significance of the observed differences were obtained by analysis of variance
(ANOVA) and Tukey post-hoc test.
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3.1.2 3-Hydroxy Fatty Acids (3-HFAs) Induce Retinal Pigmented Epithelial
Cell (ARPE-19) Lipoapoptosis
To examine whether treatment of 3-HFA to retinal cells induce
lipoapoptosis; we assessed the biochemical characteristics nuclear
morphological changes of lipoapoptosis using DNA-binding dye, 4’, 6-diamidino2-phenylindole (DAPI) and epifluorescence microscope. ARPE-19 cells treated
with 3-HPA or 3-HMA showed increased characteristic nuclear morphological
changes like nuclear fragmentation, pyknosis or chromatin condensation and cell
shrinking compared to vehicle treated cells. The representative phase contrast
image and DAPI stained fluorescent image of ARPE-19 cells treated with vehicle
or 3-HPA (100-250 μM) were showed in Figure 7. Representative images of
retinal cells were with 3-HMA treatment (100-250 μM) were showed in Figure 8
.We observed an increase in DAPI staining with increasing concentration of 3HPA (100-250 μM) shown in Figure 7 (C, D, E, F, G and H) and with increasing
concentration of 3-HMA compared to vehicle (100-250 μM) suggesting retinal cell
lipoapoptosis Figure 8 (C, D, E, F, G and H). There was a significant increase in
the percent apoptotic nuclei in 3-HPA or 3-HMA treated cells compared to vehicle
Figure 9 (A and B). Further, we measured caspase 3/7 activity by using
fluorophore-tagged caspase substrate and expressed as fold change of caspase
3/7 activity over vehicle treatment. Treatment of 3-HPA or 3-HMA (250 μM)
significantly increased caspase 3/7 activity compared to vehicle treated cells
Figure 9 (C and D). These data suggest that 3-HFAs induces retinal pigment
epithelial cell lipoapoptosis.
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Evidence for cell death in APRE-19 cells with 3-HFA treatment
Another way to test cell death is by measuring nicotinamide adenine
dinucleotide (NAD)-dependent cellular oxidoreductase enzymes. These enzymes
reflect the metabolic activity of the cells and can reduce the tetrazolium dye, 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). We measured
the MTT reduction and formazan formation as an indicator of cell survival in
APRE-19 cells with 3-HPA or 3-HMA treatment and expressed as percent cell
survival. The 3-HMA (100-250 μM) treated cells showed a significant decrease in
percent cell survival compared to the vehicle treated cells shown in Figure 9 (E).
Also, treatment of 3-HPA (100-250 μM) significantly decreased the percent cell
survival in ARPE-19 cells compared to vehicle treated cells shown in Figure 9
(F). The reduction in the cell survival with 3-HFA treatment was due to the toxic
role of 3-HFA in altering mitochondrial functions. These data suggest that 3-HFA
induces mitochondrial abnormalities and alters mitochondrial cellular and
metabolic functions in ARPE-19 cells.
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Figure 7 Representative phase contrast and fluorescent DAPI stained live
cell images of ARPE-19 cells with 3-HPA treatment. This representative figure
shows that 3-hydroxy palmitic acids (3-HPA) induced nuclear morphological
changes in retinal pigment epithelial cell (ARPE-19) lipoapoptosis. (A and B) are
vehicle cells. (C-H) are ARPE-19 cells were treated with different concentrations
of 3-HPA (100, 200, and 250 µM). Scale bar represents 200 μM.
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Figure 8 Representative phase contrast and fluorescent DAPI stained live
cell images of ARPE-19 cells with 3-HMA treatment. This representative
figure shows that 3-hydroxy myristic acids (3-HMA) nuclear morphological
changes in in retinal pigment epithelial cell (ARPE-19) lipoapoptosis. (A and B)
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are vehicle cells. (C-H) are ARPE-19 cells were treated with different
concentrations of 3-HMA (100, 200, and 250 µM). Scale bar represents 200 μM.
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Figure 9 Evidence for cell death in APRE-19 cells with 3-HFA treatment. A)
Apoptotic nuclei percent for ARPE-10 cells treated with different concentrations
of 3-hydroxy myristic acid (3-HMA) (100- 250 µM) and B) Cells treated with 3hydroxy palmitic acid (3-HPA) (100-250 µM). C) Caspase 3/7 activity represented
as fold change in ARPE-19 cells treated with 3-HMA D) cells treated with 3-HPA.
E and F) Percent cell survival of ARPE-19 with different concentrations of 3-HMA
or 3-HPA treatment. * indicates P-value with different level of significance,
*(<0.05). ** (<0.01), and ***(<0.001). The differences in the apoptotic changes
reached a statistical significance by obtaining that using ANOVA and Tukey test.

3.1.3 Saturated Free Fatty Palmitic Acid (PA) and Myristic Acid (MA) Did Not
Induce Retinal Pigment Epithelial Cell Lipoapoptosis
Similarly, ARPE-19 cells were treated with palmitic acid (PA) or myristic
acid (MA) with different concentrations like 100, 150, 200 and 250 μM to
emphasize the role of saturated free fatty acids in cell apoptosis. Treatment of
PA or MA did not increase the percent retinal cell lipoapoptosis compared to
vehicle treated cells shown in Figure 10 and 11 (A, B, C, D, E, F, G, H, I, and J).
The percent of apoptotic nuclei and caspase 3/7 activity did not show any
difference in apoptosis in vehicle and retinal cells were treated with PA or MA
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shown in Figure 12 (A, B, C and D). Together, the treatment of saturated free
fatty acids in retinal cells (ARPE-19) did not induce lipoapoptosis.
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Figure 10 Representative phase contrast and fluorescent DAPI stained live cell
images of ARPE-19 cells with MA treatment. This representative figure shows that
myristic acids (MA) did not increased staining of DAPI suggesting no change in
characteristics of nuclear morphological changes in in retinal pigmented epithelial cell
(ARPE-19) lipoapoptosis. (A and B) are vehicle cells. (C, D, E, F, G, H, I and J) ARPE19 cells were treated with different concentrations of MA (100, 150, 200, and 250 µM).
Scale bar represents 200 μM.
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Figure 11 Representative phase contrast and fluorescent DAPI stained live
cell images of ARPE-19 cells with PA treatment. This representative images
show that palmitic acids (PA) did not increase staining of DAPI suggesting no
change in characteristics of nuclear morphological changes in in retinal pigment
epithelial cell (ARPE-19) lipoapoptosis. (A and B) vehicle treated cells. (C, D, E,
f, G, H, I and J) ARPE-19 cells were treated with different concentrations of PA
(100, 150, 200, and 250 µM). Scale bar represents 200 μM.

A

B

10

10

Apoptotic Nuclei (%)

Apopototic Nuclei (%)

MA
8
6
4
2

PA
8
6
4
2
0

0

Veh

Veh

100

150

200

250

Caspase 3/7 Activity
(fold change)

Casepase 3/7 acivity
(fold change)

3

2

1

0
veh

100

150

200

D

MA

3

150

200

250

Concentrations (µM)

250

Concentrations (µM)

Concentrations (µM)

C

100

PA

2

1

0
veh

100

150

200

250

Concentratopns (µM)

46
Figure 12 Apoptotic nuclei percent for ARPE-10 cells treated with different
concentrations of myristic acid (MA) (100-250 µM) (A) and ARPE-19 cells treated
with different concentrations of palmitic acid (PA) (100-250 µM) (B). Caspase 3/7
activity in ARPE-19 cells treated with MA (C) and PA (D). * indicates P-value with
different level of significance, *(<0.05). ** (<0.01), and ***(<0.001).

3.1.4 Biochemical Hallmark of Apoptosis
Cell lysates of retinal cells treated with 3-HPA or 3-HMA were collected
after 12, 18, and 24 hours of treatment. Western analysis showed that there was
a dramatic increase in the expression of cleaved PARP in both 3-HMA and 3HPA treated cells compared to vehicle treatment shown in Figure 13. Further,
we observed that the levels of pro-apoptotic BH3 domain containing proteins,
PUMA (p53 upregulated modulator of apoptosis) were upregulated after 12-24
hours of 3-HPA or 3-HMAs treatment in ARPE-19 cells. We have observed
caspase 3/7 activation with 3-HPA or 3-HMA treatment in retinal cells.
Immunoblot analysis of active caspase 3 or cleaved-caspase 3 were increased in
both 3-HMA and 3-HPA treated cells after 12-24 hours compared to vehicle
treated retinal cells shown in Figure 13. Actin was used for control loading and
showed no change among different time points of treatment and vehicle treated
cells. These data suggest that the activation of pro-apoptotic proteins and the
initiation of intrinsic pathway of apoptosis in 3-HPA or 3-HMA treated ARPE-19
cells.
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Figure 13 Immunoblot analysis of Cleaved PARP, PUMA, Cleaved Caspase 3,
and Actin in vehicle and 3-HPA/3-HMA treated ARPE-19 cells. Vehicle cells were
isopropanol treatment and 3-HPA (250 µM) or 3-HMA (250 µM) treated cell
lysates were analyzed after 12, 18, and 24 hours of treatment.

3.1.5 Palmitoleic Acid (PO) Protects Against 3-HFA-Induced Lipotoxicity
Palmitoleic acid (PO) is a mono-unsaturated omega-7 fatty acid and has
been shown to be protective against free fatty acid-induced hepatocyte and
cholangiocyte lipotoxicity (Yang, H., Miyahara, & Hatanaka, 2011); (Yang, Z. H.
et al., 2011). To determine the beneficial role of PO in protecting ARPE-19 cells
against the lipotoxicity, we co-treated 200 μM of PO with 3-HPA or 3-HMA for 24
hours. Similar to data presented in Figure 9 (A and B), we observed that 3-HPA
or 3-HMA increased percent apoptotic nuclei compared to vehicle treatment and
the cotreatment of PO and 3-HPA or 3-HMA showed a dramatic decrease in
percent apoptotic nuclei in retinal pigment epithelia cell shown in Figure 14 (A
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and B). Similarly, cotreatment of PO and 3-HFAsalso reduced caspase 3/7
activity compared to cells treated with 3-HPA or 3-HMA alone shown in Figure
14 (C and D). In addition, percent cell survival was significantly protected when
ARPE-19 cells were co-treated with 3-HPA or 3-HMA with PO, compared to 3HPA or 3-HMA alone, which decreases cell survival shown in Figure 14 (E and
F). These data suggest that PO protects against 3-HFA-induced retinal cell
lipoapoptosis.
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Figure 14 Apoptotic cell death and caspase activation in ARPE-19 cells
treated with 3-HPA or 3-HMA along with palmitoleate. Apoptotic nuclei
percent for ARPE-19 cells treated with 3-HMA and PO (A) and cells treated with
3-HPA and PO (B). Caspase 3/7 activation in ARPE-19 cells treated with 3-HMA
and PO (C) and cells treated with 3-HPA and PO (D). Percent cell survival of
ARPE-19 cells with 3-HMA (E) or 3-HPA (F) with and without palmitoleate (PO).
Data represents mean ± SEM from five independent experiments, n=5. *
indicates P-value with different level of significance of 3-HPA or 3-HMA
compared to vehicle, *(P<0.05). ** (P<0.01), and ***(P<0.001). #P>0.05
compared to 3-HPA or 3-HMA.

3.1.6 Retinal Cells Accumulate Lipid Droplets with 3-HPA or 3-HMA
Treatment
To investigate whether retinal cells accumulate lipid droplets, ARPE-19
cells were stained with oil red O’ after cells were treated with 250 μM of 3-HPA or
3-HMA for 24 hours with and without palmitoleate (PO). We observed that
ARPE-19 cells with 3-HPA or 3-HMA treatment accumulated lipid droplets
comparing to vehicle treated cells shown in Figure 15. The lipid droplets
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accumulation is reduced in retinal cells co-treated with PO and 3-HPA or 3-HMA
shown in Figure 15. We also quantitated Oil red O’ staining in retinal cells with 3HFA treatment by measure the absorbance of stained cells at 490 nm (Fei Z et
al, 2011). ARPE-19 cells treated with 3-HPA or 3-HMA showed increased Oil red
O staining and co-treatment of PO with 3-HPA or 3-HMA significantly reduced
lipid accumulation in retinal cells shown in Figure 16 (A and B). These data
suggest that palmitoleate protects against 3-HFA-induced lipotoxicity in retinal
cells by decreasing the accumulation of lipid droplets. Further studies are needed
to elucidate the mechanism of PO preventing lipid droplet accumulation in retinal
cells.
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Figure 15 Lipid droplet accumulation for ARPE-19 cells. Cells stained with
Oil red O’ assay visualized under light microscope. Control cells were treated
with Vehicle (A) and Palmitoleate (B). Retinal cells with 250 μM of 3-HMA (C)
and 3-HPA treatment (E) for 24 hours showed increased Oil red ‘O’ staining. Cotreatment of palmitoleate (PO) with of 250 µM 3-HPA or 3-HMA (D and F)
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resulted in decreased Oil red ‘O’ staining. The images are representative images
from three independent experiments, n=3.
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Figure 16 Oil red O’ assay absorbance in ARPE-19 cells. ARPE-19 cells
treated with only 3-HMA (250 µM) and both 3-HMA (250 µM) and PO (200 µM)
(A). Cells treated with 3-HPA (250 µM) alone and co-treated with 3-HPA (250
µM) and PO (200 µM) (B). * indicates P-value with different level of significance
of 3-HPA or 3-HMA compared to vehicle, *(<0.05). ** (<0.01), and ***(<0.001). #
indicates P-value for 3-HPA or 3-HMA with PO compared to 3-HPA or 3-HPA

3.1.7 3-HFA-Induces Retinal Cell lipoapoptosis is c-Jun N-terminal Kinase
Activation.
To determine the critical role of c-Jun N-terminal kinase (JNK) in 3-HFAinduced ARPE-19 lipoapoptosis; we used small molecule inhibitors of JNK
(SP600125, JNKi). ARPE-19 cells were treated with 3-HPA or 3-HMA alone and
co-treated with JNKi. First, we measured the activation of caspase in cells
treated with only 3-HFAs and co-treatment of 3-HFAs with JNK inhibitor. Both 3-
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HMA and 3-HPA treatment increases caspase 3/7 activation in retinal cells and
co-treatment of 3-HFAs with SP600125 (JNK inhibitor) resulted in a significant
protection against 3-HFAs induced caspase 3/7 activation Figure 17 (A and B).
Decreased percent cell survival of retinal cells with 3-HPA or 3-HMA treatment
after 24 hours were significantly prevented with the cotreatment of JNK-i Figure
17 (C and D).

3.1.8 3-HFA Induces Retinal Cell Lipoapoptosis is Caspase Dependent
To determine the critical role of caspase in 3-HFA-induced ARPE-19
lipoapoptosis; we used pan-caspase inhibitor (Z-VAD fmk). ARPE-19 cells were
treated with 3-HPA or 3-HMA alone and co-treated with Z-VAD. First, we
measured the activation of caspase in cells treated with only 3-HFAs and cotreatment of 3-HFAs with caspase inhibitor. We observed that co-treatment of 3HFAs with Z-VAD-fmk decreased the 3-HFA-induced caspase activation in
ARPE-19 cells Figure 18 (A and B). Inhibition of caspase activity using Z-VAD
also protected 3-HFA-induced apoptosis ARPE-19 cells as evidenced by an
increase in percent cell survival with 3-HFA and Z-VAD co-treated retinal cells
Figure 18 (C and D).
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Figure 17 Caspase 3/7 activity and percent cell survival in ARPE-19 cells
treated with JNK-i. Caspase 3/7 activity were measured when cells were treated
with 3-HMA and co-treated with 3-HMA and JNK inhibitor (SP600125, JNKi) (A)
or treated with only 3-HPA or co-treated with 3-HPA and JNK-i. (B). Percent cell
survival were measured when cells were treated with only 3-HMA or co-treated
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Data represent mean ± SEM from five independent experiments, n=5. *indicates
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P-value with different level of significance of 3-HPA or 3-HMA compared to
vehicle (veh), *(<0.05). ** (<0.01), and ***(<0.001). # P<0.05 compared to 3-HMA
or 3-HPA treatment
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Figure 18 Caspase 3/7 activity and percent cell survival in ARPE-19 cells
treated with Z-VAD. Caspase 3/7 activity were measured when cells were
treated with 3-HMA and co-treated with 3-HMA and caspase inhibitor (Z-VAD
fmk) (A) or treated with only 3-HPA or co-treated with 3-HPA and Z-VAD (B).
Percent cell survival were measured when cells were treated with only 3-HMA or
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co-treated with 3-HMA Z-VAD (C) and only 3-HPA and co-treated with 3-HPA
and Z-VAD (D). Data represent mean ± SEM from five independent experiments,
n=5. *indicates P-value with different level of significance of 3-HPA or 3-HMA
compared to vehicle (veh), *(<0.05). ** (<0.01), and ***(<0.001). # P<0.05
compared to 3-HMA or 3-HPA treatment
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4. CHAPTER IV: DISCUSSION, CONCLUSION, AND FUTURE
DIRECTIONS

4.1 Discussion
This study confirms the lipotoxic role of 3-hydroxy fatty acids (3-HFAs) like
3-hydroxy palmitic acids (3-HPA) and 3-hydroxy myristic acids (3-HMA) in
inducing lipoapoptosis in retinal pigmented epithelial cells (ARPE-19).
Accumulation of 3-HFAs are involved in children with LCHAD deficiency leading
to develop pathophysiology such as retinopathy, cardiovascular disease, and
muscle atrophy. Retinopathy is a widely associated with mitochondrial
dysfunctions, however, there is a gap in knowledge on the mechanism of 3-HFAinduced retinal pigment epithelial cell lipotoxicity. The main goal of the present
study is to test lipotoxicity in retinal cells and we used a normal human
immortalized retinal pigmented epithelial cell, ARPE-19, in vitro. Lipoapoptosis is
known as programmed cell death that is caused due to the exposure of high
concentration of fatty acids. Apoptosis due to caspase activation and
mitochondrial alteration, which are characterized by oxidative stress due to
accumulating toxic free fatty acids in the circulation during obesity and metabolic
syndrome has been well established (Wajner & Umpierrez, 2016) . We
characterized retinal pigmented epithelial cell features and evaluated caspases
activity, mitochondrial functions, lipid droplets, and biochemical hallmarks of
apoptosis with 3-HFA exposure. To examine all these characteristics, cells were
treated with 3-HFAs including 3-hydroxy palmitic acids (3-HPA) or 3-hydroxy
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myristic acids (3-HMA) to mimic and simulate pathophysiological condition in
LCHAD patient’s blood circulation. Patients with defective fatty acid oxidation
metabolism especially who are deficient in the enzyme long-chain hydroxy acylCoA dehydrogenase (LCHAD), can accumulate metabolites and substrates such
as saturated free fatty acids and hydroxy fatty acids. Here we hypothesize that
the retinal cell apoptosis could contribute and result in retinopathy observed in
LCHAD deficient patient. In the present study, we demonstrated that 3-HPA or 3HMA exposure to retinal pigment epithelial cells resulted in retinal cell
lipoapoptosis. Apoptosis can leads to mitochondrial stress, caspases activation,
and lipid accumulation.
Lipotoxic role of 3-HFAs in inducing lipoapoptosis is in agreement with our
unpublished work that has shown the accumulation of 3-HFAs including 3-HMA
or 3-HPA induces hepatocyte lipoapoptosis leading to apoptosis and caspase
activation (Natarajan, S. K. & Ibdah, 2018). Additionally, previous study
conducted on human disease model created from a pluripotent stem cell (hiPSC)
differentiation to retinal cells demonstrates that retinal pigmented epithelial cells
developed pathogenic changes with retinal characteristics and nuclear
morphology suggesting the apoptosis (Padmini et al., 2015).
Mitochondria are the major site for energy metabolism and mitochondrial
mediated activation of intrinsic pathway of apoptosis is characterized with
mitochondrial permeabilization and release of cytochrome C resulting in the
formation of apoptosome and activation of caspases (Natarajan SK, 17 February
2012) . Our previous research using placenta from patients with acute fatty liver
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of pregnancy (AFLP) showed oxidative stress in the placental subcellular
organelle and maternal systemic (Natarajan, S. et al., 2010; Natarajan, S.,
Thangaraj, Eapen, Ramachandran, & Balasubramanian, 2011; Natarajan, S. K.,
Eapen, Pullimood, & Balasubramanian, 2006) . Defects in placental
mitochondrial fatty acid oxidation can channel the fatty acids to peroxisomal βoxidation and microsomal omega-oxidation. Increased peroxisomal β-oxidation
would result in the generation of hydrogen peroxide, which could: 1) damage
subcellular organelles; 2) alter redox homeostasis; 3) damage cellular redoxsensitive protein function; and 4) contribute to the cell death and disease
development. Further, placental mitochondria isolated from patients with AFLP
showed mitochondrial dysfunction and the levels of antioxidants such as
tocopherol and retinol were decreased in the systemic circulation of AFLP
patients compared to controls suggesting oxidative stress in maternal systemic
circulation in patients with AFLP. Further, we have shown animals treated with
valproate, an inhibitor of liver mitochondrial β-oxidation, showed hepatic
mitochondrial dysfunction, oxidative stress and microvesicular steatosis in the
liver suggesting that a blockage in mitochondrial β-oxidation would induce
hepatic mitochondrial dysfunction and oxidative stress in the liver (Natarajan, S.
et al., 2010; Natarajan, S. et al., 2011; Natarajan, S. K. et al., 2006). Similar to
the placental and liver cells; in the present work retinal cells exposed to 3-HPA
resulted significant alteration in the mitochondrial bioenergetics and functions.
Mitochondrial dysfunction and damage results in alteration to mitochondrial
respiration with the exposure of lipotoxic 3-HFA metabolites. In ARPE-19 cells
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that were treated with 3-HPA, there was a significant decrease in the ATP
production, basal respiration and spare respiratory capacity, and coupling
efficiency. All these abnormalities resulted to compensate the stress that was
induced by the accumulation of 3-HFA. The findings suggest that mitochondrial
stress is the mechanism that contributes to the 3-HFA-induced ARPE-19 cell
death. Similar to our findings, a recent study showed that defective mitochondria
resulted in altering the respiratory chain and coupling efficiency which increase
reactive oxygen species (ROS) (Radek, Marco, & Heinz, 2014).
Retinal pigment epithelial cells (RPE) functions to maintain recycling of 11cis-retinaldehyde, absorbs excess light and contributes to the phagocytosis of
photoreceptors fragments (Tivadar O., Palczewska G., Palczewski K., 2011 May
12). RPE cells also store retinyl esters in retinosomes and excess fatty acids as
lipid droplets (Brink. D. et al., 2018). Lipid droplets accumulation in RPE can
impair normal cell signaling leading to cellular dysfunction and apoptotic cell
death (Meyer et al., 2011). Similarly, ARPE-19 cells have been shown to
accumulate lipid droplets (Chena et al., 2019) . It has also been shown that
retinal cells can accumulate lipid droplets during LCHAD deficiency (Chena et al.,
2019) Further free fatty acid and high glycose exposure during obesity and
metabolic syndrome has also been shown to increased lipids droplets
accumulation in retinal pigment epithelial cells (Chena et al., 2019). The retinal
dysfunction due to free fatty acid and high glucose exposure to retinal cells has
been demonstrated as the mechanism for the progression of diabetic retinopathy
which resulted in retinal atrophy (Chena et al., 2019). Rudolf et al., showed that

62
retinal pigment epithelial cells can also accumulate lipid droplets with aging in
human retina through accumulations of lipoproteins particles resulting in agerelated macular degeneration (Rudolf & Curcio, 2009). Further, it has been
shown that overexpression of fatty acid transport protein (FATP) in retinal cells of
drosophila and mice enhanced lipid droplets accumulation (Brink. D. et al., 2018).
Under normal conditions, these lipid droplets have a beneficial effect on the
retinal cells and photoreceptors. However, under vitamin A deficiency diet, the
accumulation lipids droplets were toxic which disturbed the photoreceptors
homeostasis (Van Den et al., 2018).
Our lab has previously shown that forkhead family of transcription factor
class O3 (FoxO3) is activated in hepatocytes that were treated with 3-HFAs
(Natarajan, S. K. et al., 2017) . The activation of FoxO3 is associated with cell
death signaling, because FoxO3 can transcriptionally upregulates the proapoptotic protein, like BIM, PUMA and NoxA which can induce lipoapoptosis
(Natarajan, S. K. et al., 2017). In the present study, we observed biochemical
evidence of apoptosis such as increased levels of PUMA in ARPE-19 cells
treated with 3-HPA or 3-HMA. However, the role of FoxO3 activation and the
critical role of pro-apoptotic protein, PUMA in retinal lipoapoptosis requires
further investigation. The increased expression of pro-apoptotic BH3 domain
containing protein, PUMA indicates the activation of intrinsic pathway of
apoptosis. Increased levels of PUMA can act against anti-apoptotic proteins like
BCL2 and MCL1. The expression of anti-apoptotic proteins in retinal pigment
epithelial cells with 3-HFAs requires further investigation. Caspase 3/7 enzyme
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activity is responsible for cleaving downstream caspase substrates such as poly
adenosine-ribose polymerase (PARP). The increased levels of caspase
substrate, cleaved PARP and cleaved caspase 3, are key markers for the late
phase of the apoptosis were evident in retinal cells exposure to 3-HFA. In
addition to caspase substrate, inhibition of caspases using small molecular
inhibitor blocked 3-HFA-induced lipoapoptosis in retinal cells suggestions the
critical role of caspase activation during retinal pigment cell lipoapoptosis. In
summary, apoptotic hallmarks were evident when ARPE-19 cells were exposed
to higher concentrations of 3-HPA or 3-HMA, suggesting the involvement of
retinal cell lipoapoptosis in the development of retinopathy in patients with
LCHAD deficiency.
In the present study, we proposed a dietary nutrient intervention to protect
against 3-HFA-induced lipotoxicity in retinal cells with palmitoleic acid (PO)
supplementation. PO is an omega 7-mono unsaturated fatty acids and PO has
been shown to protect against saturated free fatty acid-induced hepatocyte and
cholangiocyte lipoapoptosis (Akazawa, 2010). PO treatment has been shown to
abolish palmitate-induced endoplasmic reticulum (ER) stress response, JNK
activation, mitochondrial pro-apoptotic mediators, and lipotoxicity (Akazawa,
2010) . Further, supplementation of palmitoleate has been shown to unalter the
expression of stearoyl CoA-desaturase1 (SCD1), an enzyme that can convert
palmitate into palmitoleate, however palmitoleate (PO) increased lipid droplets
accumulation and decreases the lipotoxicity of saturated FFAs in hepatocytes
(Akazawa, 2010) . In addition, decreased expression of SCD1 were found to
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enhance palmitate-induced trophoblast lipotoxicity (Yang, C., Lim, Bazer, &
Song, 2018). Nevertheless, the in vivo effect of PO on retinopathy still needed to
be elucidated. PO is involved in many processes associated with cell function,
acts as anti-apoptotic fatty acid, and improves lipid profile in obese mice (Yang,
H., Miyahara, & Hatanaka, 2011). Further, supplementation of PO significantly
reduces the hepatic triglyceride levels and lipid droplets accumulation in the liver
of diabetic mice (Yang, H. et al., 2011). In the present study, our data
demonstrated the positive role of PO in protecting against lipoapoptosis.
Additionally, lipid droplets accumulation in ARPE-19 has been decreased
significantly when cells treated with PO compared to 3-HFAs treatment. Also,
palmitoleate protects against 3-HFA-induced retinal cell lipoapoptosis. We
observed that treatment of JNK-inhibitor protected against 3-HFA induced retinal
lipoapoptosis, these data suggest that JNK plays a critical role in retinal
lipoapoptosis. Saturated free fatty acids are known to active JNK-dependent
hepatocyte lipoapoptosis (Malhi. H., Bronk. S., Werneburg. N., and Gores. G.,
2006). However, our lab has previously showed that JNK is not critical for
cholangiocyte lipoapoptosis (Natarajan, S. K. et al., 2014). Here, we speculate
that PO protection could involve prevention of JNK activation, further studies are
needed to demonstrate the role of JNK signaling with PO supplementation. Chen
et al., showed that JNK could transitionary upregulates the expression of PUMA
protein during cell death process (Chena et al., 2019). However, it is still not clear
whether treatment with PO could alter the transcriptional activity of JNK for the
protection against retinal lipoapoptosis and requires further investigation.
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Further, demonstrating the retinal cell lipoapoptosis in animal models of LCHAD
deficiency and dietary supplementation of palmitoleate protecting against retinal
injury, retinopathy and lipoapoptosis requires further investigation.

4.2 Conclusions and Future Directions
In conclusion, the data from the present study show that 3-hydroxy fatty
acids can induce lipoapoptosis in retinal pigment epithelial cells. The
mechanisms are involved in lipoapoptosis were; caspase 3/7 activation,
mitochondrial dysfunction, and activation of pro-apoptotic protein PUMA. All
these events together support the hypothesis that 3-HFA induces lipotoxicity in
retinal cells in vitro. Also, we show evidence for palmitoleate protection against
3-HFA induced lipotoxicity. The data presented in this study were from ARPE-19
cell line. Our next steps are to use LCHAD knockdown animal and confirm the
lipotoxic role of 3-hydroxy fatty acids in inducing the retinal damage and
retinopathy. In addition, we would also like to use CRISPR/Cas9 system to
introduce pathogenic mutation in LCHAD encoding gene, HADHA in retinal cells
to test retinal cell lipoapoptosis. Further investigations are also required to
understand the mechanism of PO in protecting against 3-HFA-induced retinal cell
lipotoxicity.
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